1 Epidemiological and Clinical Features, Treatment Status, and Economic 2 Burden of Traumatic Spinal Cord Injury in China

3 Hengxing Zhou^{1,2,#}, Yongfu Lou^{2,#}, Lingxiao Chen^{1,3,#}, Yi Kang^{2,#}, Lu Liu⁴, Zhiwei Cai⁵, David B
4 Anderson³, Wei Wang², Chi Zhang¹, Jinghua Wang⁶, Guangzhi Ning², Yanzheng Gao⁷, Baorong He⁴,
5 Wenyuan Ding⁸, Yisheng Wang⁹, Wei Mei¹⁰, Yueming Song¹¹, Yue Zhou¹², Maosheng Xia¹³, Huan
6 Wang¹⁴, Jie Zhao¹⁵, Guoyong Yin¹⁶, Tao Zhang¹⁷, Feng Jing¹⁸, Rusen Zhu¹⁹, Bin Meng²⁰, Li Duan²¹,
7 Zhongliang Deng²², Zhongmin Zhang²³, Desheng Wu²⁴, Yajun Liu²⁵, Zhengdong Cai²⁶, Lin Huang²⁷,
8 Zhanhai Yin²⁸, Kainan Li²⁹, Shibao Lu³⁰, Xu Cao³¹, Shiqing Feng^{1,2,*}

9 1. Department of Orthopaedics, Qilu Hospital, Shandong University Centre for Orthopaedics,
10 Cheeloo College of Medicine, Shandong University, Shandong, China.

11 2. Department of Orthopaedics, Tianjin Medical University General Hospital, Tianjin Medical
12 University, International Science and Technology Cooperation Base of Spinal Cord Injury, Tianjin
13 Key Laboratory of Spine and Spinal Cord, Tianjin, China.

14 3. Institute of Bone and Joint Research, Kolling Institute, Sydney Medical School, Faculty of
15 Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

16 4. Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.

17 5. Department of Burns and Plastic Surgery, The Fourth Medical Center of PLA General Hospital,
18 Beijing, People's Republic of China.

19 6. Laboratory of Epidemiology, Tianjin Neurological Institute, Department of Neurology, Tianjin
20 Medical University General Hospital & Tianjin Neurological Institute, Key Laboratory of
21 Post-Neuroinjury Neuro-repair and Regeneration in Central Nervous System, Ministry of Education
22 and Tianjin City, Tianjin, China.

23 7. Department of Orthopedics, Henan Provincial People's Hospital, Zhengzhou, China.

24 8. Department of Spinal Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang,
25 China.

26 9. Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou,
27 China.

28 10. Department of Spine Surgery, Zhengzhou Orthopaedics Hospital, Zhengzhou, China.

29 11. Department of Orthopedic Surgery and Orthopedic Research Institute, West China Hospital,
30 Sichuan University, Chengdu, China.

31 12. Department of Orthopaedics, Xinqiao Hospital, Army Medical University, Chongqing, China.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 32 13. Department of Orthopaedics, The First Affiliated Hospital of China Medical University,
33 Shenyang, China.
- 34 14. Department of Spinal Surgery, Shengjing Hospital of China Medical University, Shenyang,
35 China.
- 36 15. Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai
37 Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- 38 16. Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University,
39 Nanjing, China.
- 40 17. Department of Spinal Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital,
41 Shanghai, China.
- 42 18. Department of Spinal Surgery, Tianjin Hospital, Tianjin, China.
- 43 19. Department of Spine Surgery, Tianjin Union Medical Center, 190 Jieyuan Road, Hongqiao
44 District, Tianjin, China.
- 45 20. Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University,
46 Suzhou, China.
- 47 21. Department of Orthopaedics, Shenzhen Intelligent Orthopaedics and Biomedical Innovation
48 Platform, Guangdong Artificial Intelligence Biomedical Innovation Platform, Shenzhen Second
49 People's Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center,
50 Shenzhen, China.
- 51 22. Department of Orthopaedics, The Second Affiliated Hospital of Chongqing Medical University,
52 Chongqing, China.
- 53 23. Department of Orthopaedics, The Third Affiliated Hospital of Southern Medical University,
54 Guangzhou, Guangdong Province, China.
- 55 24. Department of Spine Surgery, Shanghai East Hospital Affiliated, Tongji University School of
56 Medicine, Shanghai, China.
- 57 25. Department of Spine Surgery, Beijing Jishuitan Hospital, The 4th Clinical Hospital of Peking
58 University Health Science Center, Beijing, China.
- 59 26. Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiao Tong University School
60 of Medicine, Shanghai, China.
- 61 27. Department of Orthopaedics, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,
62 Guangzhou, China.
- 63 28. Department of Orthopaedics, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an,
64 China.

65 29. Department of Orthopaedic Surgery, Affiliated Hospital of Chengdu University, Chengdu,
66 China.

67 30. Beijing Xuanwu Hospital, Capital Medical University, Beijing, China; National Geriatric
68 Diseases Research Center, Beijing, China.

69 31. Department of Orthopedic Surgery, Johns Hopkins University School of Medicine, Baltimore,
70 MD, USA.

71 ***Corresponding to:**

72 Professor. Shiqing Feng, PhD, Department of orthopaedics, Tianjin Medical University General
73 Hospital, Tianjin Medical University, International Science and Technology Cooperation Base of
74 Spinal Cord Injury, Tianjin Key Laboratory of Spine and Spinal Cord, Tianjin, 300052, P.R. China;
75 Department of orthopaedics, Qilu Hospital, Shandong University Centre for orthopaedics, Cheeloo
76 College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China. Tel/fax:
77 +8602288366139. Email: sqfeng@tmu.edu.cn

78 [#]These authors contributed equally to this work.

Abstract

Background China has the largest population of traumatic spinal cord injury (TSCI), but has not yet performed a national-level study on its epidemiological and clinical features, treatment status, and economic burden.

Methods A total of 14 754 patients were recruited between January 2013 and December 2018 from 37 hospitals in 11 provinces and municipalities, which represented all geographical divisions of China. The percentage of TSCI in hospitalized patients and the percentage of TSCI in hospitalized patients through the orthopaedic departments were calculated. The treatment status, total and daily costs were collected.

Results The percentage of TSCI in hospitalized patients and the percentage of TSCI in hospitalized patients through the orthopaedic departments did not change significantly overall (APC= -0.5%, 95% CI: -3.0 to 2.1 and -1.6%, -4.9 to 1.8, respectively). A total of 10 918 (74.0%) patients received surgery after TSCI. However, only 3.0% of patients underwent surgery received surgery less than 24 hours after injury. A total of 2 084 (14.1%) patients were treated with methylprednisolone sodium succinate/methylprednisolone (MPSS/MP) at a high dose (≥ 500 mg) and 641 (4.3%) patients receiving it within 8 hours. The total costs for acute TSCI decreased (-4.8%, -6.2 to -3.4), while the daily costs did not change significantly (0.5%, -1.2 to 2.2).

Conclusions This study revealed epidemiological and clinical features, treatment status, and economic burden of TSCI that occurred in China from 2013 to 2018.

- 101 **Funding** National Key Research and Development Project of Stem Cell and
- 102 Transformation Research (2019YFA0112100).

Introduction

Traumatic spinal cord injury (TSCI) is a significant life event which can lead to permanent disability or even death (*Ahuja et al., 2017; National Spinal Cord Injury Statistical Center, 2016*). TSCI can be treated with surgery, glucocorticoids or other non-surgery treatments; followed by a period of rehabilitation (*Robert R Hansebout, 2021*). These treatments bring a heavy financial burden to patients and their families, with direct costs ranging from US\$ 1.1 to 4.7 million per patient over their lifetime (*National Spinal Cord Injury Statistical Center, 2016*). Over the past three decades, there has been an increased understanding of the burden of TSCI globally, attributable to epidemiological studies, such as the Global Burden of Disease (GBD) Study (*GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators, 2019*). The GBD studies concluded that the number of people with TSCI would increase globally (*Institute for Health Metrics and Evaluation, 2021*). The GBD study did report limitations with the accuracy of data in some regions however, and did not collect data on the severity of TSCI, limiting calculations on disease burden (*Badhiwala et al., 2019*). Authors of the GBD study recommended more researches be conducted into developing countries and the collection of more comprehensive TSCI data (*Badhiwala et al., 2019*). Currently, the high-quality research in developing countries is still limited, especially in China which is one developing country of significance, given it possesses the largest population of any country and therefore has capacity to significantly influence global rates of TSCI (*Institute for*

124 *Health Metrics and Evaluation, 2021*). One major limitation of the current data
 125 available from China is that most of them are from regional areas (*Yuan et al.,*
 126 *2018*).

127

128 The purpose of this study was to identify the epidemiological and clinical features,
 129 treatment status, and economic burden of TSCI in China from 2013 to 2018.

Methods

We followed STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement (*von Elm et al., 2007*).

Study population

We established the Chinese multicentre TSCI registry project (CMTSCIRP, ChiCTR1800019691) which was a national, hospital-based retrospective study. Any patients who sustained a TSCI between January 2013 and December 2018 in China and attended a large general hospital or orthopaedic speciality centre were included. The sites included 37 hospitals from the seven geographical regions (Central China, Northern China, Eastern China, Southern China, Northwest China, Southwest China, and Northeast China) and four municipalities (Beijing, Shanghai, Tianjin, and Chongqing) of China. For each region or municipality, we selected between three and four hospitals that were either large general hospitals or orthopaedic speciality centres (Figure supplement 1). The study was approved by Medical Research Ethics Committee of Tianjin Medical University General Hospital [IRB2018-154-01] and all participating centres.

Spinal cord injury (SCI) is defined as damage to the spinal cord that temporarily or permanently causes its functional changes, and TSCI occurs when an external physical impact (such as falls, motor vehicle injuries, or sports-related injuries) acutely damages the spinal cord (*Ahuja et al., 2017*).

152

153 With the help of the librarian, we used the following strategy to retrieve TSCI cases.

154 We identified TSCI mainly using medical terms in Chinese ("Spinal fractures",

155 "Cervical fractures", "Thoracic fractures", "Lumbar fractures", "Sacral fractures",

156 "Spinal cord injury", "Cervical spine fracture with spinal cord injury", "Thoracic

157 spine fracture with spinal cord injury", "Lumbar spine fracture with spinal cord

158 injury", "Cervical spinal cord injury", "Thoracic spinal cord injury", "Lumbar spinal

159 cord injury", "Cauda equina injury", "Nerve injury", "Quadriplegia", "Paraplegia",

160 "Incomplete quadriplegia", and "Incomplete paraplegia"), as it was difficult to unify

161 case codes due to diversities in codes used by different hospitals. And the Tenth

162 Revision of the International Classification of Diseases (ICD-10) codes involved in

163 TSCI from the International Spinal Cord Injury Community Survey (InSCI) Group

164 was also used to complement and refine the medical terms [S12 (Fracture of the

165 neck), S12.0 (Fracture of first cervical vertebra), S12.2 (Fracture of other specified

166 cervical vertebra), S13.0 (Traumatic rupture of cervical intervertebral disk), S13.2

167 (Dislocation of other and unspecified parts of neck), S13.4 (Sprain and strain of

168 cervical spine), S14 (Injury of nerves and spinal cord at neck level), S14.0

169 (Concussion and edema of cervical spinal cord), S14.1 (Other and unspecified

170 injuries of cervical spinal cord), S17 (Crushing injury of neck), S19 (Other and

171 unspecified injuries of neck), S22 (Fracture of ribs, sternum and thoracic spine),

172 S22.0 (Fracture of thoracic vertebra), S23.1 (Dislocation of thoracic vertebra), S24

173 (Injury of nerves and spinal cord at thorax level), S24.0 (Concussion and edema of

174 thoracic spinal cord), S24.1 (Other and unspecified injuries of thoracic spinal cord),
175 S28 (Crushing injury of thorax and traumatic amputation of part of thorax), S29
176 (Other and unspecified injuries of thorax), S32 (Fracture of lumbar spine and pelvis),
177 S32.0 (Fracture of lumbar vertebra), S33.1 (Dislocation of lumbar vertebra), S34.0
178 (Concussion and edema of lumbar spinal cord), S34.1 (Other injury of lumbar spinal
179 cord), S34.3 (Injury of cauda equina), S38 (Crushing injury and traumatic
180 amputation of part of abdomen, lower back and pelvis), S39 (Other and unspecified
181 injuries of abdomen, lower back and pelvis), T02.0 (Fractures involving head with
182 neck), T02.1 (Fractures involving thorax with lower back and pelvis), T04.1
183 (Crushing injuries involving thorax with abdomen, lower back and pelvis), T04.2
184 (Crushing injuries involving multiple regions of upper limbs), T06.0 (Injuries of
185 brain and cranial nerves with injuries of nerves and spinal cord at neck level), T06.1
186 (Injuries of nerves and spinal cord involving other multiple body regions), T09.3
187 (Injury of spinal cord, level unspecified), T09.4 (Injury of unspecified nerve, spinal
188 nerve root and plexus of trunk), T91.1 (Sequelae of fracture of spine), T91.3
189 (Sequelae of injury of spinal cord), G82 (Paraplegia and tetraplegia), G82.0 (Flaccid
190 paraplegia), G82.1 (Spastic paraplegia), G82.2 (Paraplegia, unspecified), G82.3
191 (Flaccid tetraplegia), G82.4 (Spastic tetraplegia), G82.5 (Tetraplegia, unspecified),
192 G83.4 (Cauda equina syndrome)] (*Gross-Hemmi et al., 2017*). All cases were
193 checked by trained investigators. Non-traumatic spinal cord injury (such as tumor or
194 degenerative compression) was excluded.

195

Outcomes

Considering the accessibility of data, the percentage of TSCI in hospitalized patients of 23 hospitals were calculated from: the number of TSCI patients/the number of hospital admissions. We also calculated the percentage of TSCI in hospitalized patients through the orthopaedic departments from the same 23 hospitals as: the number of TSCI patients/the number of orthopaedic departments admissions.

According to the definition for early surgery (<24 h) mentioned in previous studies (*Robert R Hansebout, 2021; Badhiwala et al., 2021*) and the interquartile distribution of data in this study, surgery timing was divided to two sections: 1. "<24 h"; 2. "<4.0 d", "4.0-11.9 d" followed by ">11.9 d". Off-label use of methylprednisolone sodium succinate/methylprednisolone (MPSS/MP) for TSCI remains contentious (*Roberts et al., 2017*), therefore, we defined 500mg of MPSS/MP as a threshold in this study, based on the user guide (*DXY Drugs Information, 2021*). The use of MPSS/MP was divided into continuous and intermittent use. Intermittent use referred to that two or more prescriptions, with at least one day interval between arbitrary two prescriptions, were made for MPSS / MP use during hospitalization. The length of accumulated time was the sum of all days to use MPSS/MP. Although the use of MPSS/MP after SCI continues to be controversial, AOSpine organization suggested a high-dose of MPSS/MP within 8 hours of acute SCI as a treatment option in 2017 (*Fehlings et al., 2017*). The starting time to use off-label MPSS/MP (≥ 500 mg) was divided into " ≤ 8 h", and ">8 h".

There rarely has been studies on whether normal dose of MPSS/MP and the starting time affect the treatment for SCI. Therefore, based on the interquartile distribution of data from patients of continuously using MPSS/MP with a normal dose (<500 mg), the starting time of MPSS/MP use was divided into " ≤ 1.6 d", "1.6-9.0 d", and " ≥ 9.0 d". And the length of accumulated use time was divided into " ≤ 2 d", "3-5d", and " ≥ 6 d". In addition, we removed participants (1 case excluded in the high-dose group and 7 cases excluded in the normal dose group) who lacked starting time from injury to medication.

The total and daily costs were the costs during the patient's hospitalization for acute TSCI and were identified from the patient's medical record. And acute TSCI was defined as hospital admission within 14 days after spinal cord injury. The total and daily costs were converted to 2013 Chinese Yuan (CNY), discounting at an annual rate of 5%, as recommended by China guidelines for pharmacoeconomic evaluations (2020) (*Gordon, 2020*). In addition, referring to the exchange rate of CNY to USD (USA dollar, USD=100) in 2013 as CNY 619.32, the costs were showed by CNY and USD (*National Bureau of Statistics, 2021*). Non-acute TSCI patients were not included in the financial burden of this study, as acute and non-acute TSCI patients were treated differently during hospitalization, which would bias the estimate (*Robert R Hansebout, 2021*).

Covariates

240 Age groups in this study were divided into "15 years~", "25 years~", "35 years~",
241 "45 years~", "55 years~" and " ≥ 65 years". Occupations covered "Farmers",
242 "Workers", "Retired", "Office clerks", "Students", "Self-employed", "Civil servants",
243 "Drivers", "Teachers" and "Others" ("Unemployed" or "Freelances") based on
244 medical records. The etiological groups consisted of "Low falls" (< 1 m), "High
245 falls" (≥ 1 m), "Traffic accidents", "Struck by falling objects", "Sport related
246 injuries", "Injuries caused by others", "Work related injuries", "Sharp injuries",
247 "Massage related injuries" and "Others" ("Electric shock injuries", "Gunshot
248 wounds", "Crush injuries", "Iatrogenic injuries", etc.). Level of injury comprised
249 "Cervical", "Thoracic", "Lumbosacral", "Multi-site" and "Cauda equina", and
250 "Multi-site" referred to at least two different segments of injury (*Selvarajah et al.*,
251 2014). Severity was divided into four types: "Complete quadriplegia", "Complete
252 paraplegia", "Incomplete quadriplegia" and "Incomplete paraplegia" based on
253 degree and extent of neurological damage. The American Spinal Injury Association
254 (ASIA) Impairment Scale (AIS), which superseded the original Frankel Scale, has
255 been widely accepted among clinicians and researchers for classification of the
256 location, severity and extent of spinal cord injury, introducing several changes
257 aiming at a more consistent and objective description on the basis of the scores of a
258 standardized examination of myotomes and dermatomes (*Kirshblum et al.*, 2011).
259 Neurological function of TSCI patients admitted was evaluated using the AIS, with
260 a division into complete (AIS grade A) and 4 incomplete (AIS grade B-E) injury
261 grades, and the grades and key description were shown in Table supplement 1

(*Roberts et al., 2017*). In groups with less than 1% of the total number of patients, they were categorized as "Others" to increase the reproducibility of the results (*Harrell Jr, 2015*).

Statistical Analysis

Continuous variables were presented as a mean (standard deviation, SD) and categorical variables as numbers (percentages). Annual percentage change (APC) is usually used to estimate the event change rate during specific calendar years. Joinpoint regression analysis fits a series of joined linear models of the natural logarithm of annual incidence using calendar year as an independent variable, which is often useful to calculate the APC and corresponding 95% confidence interval (95% CI) (*Salomaa et al., 1992*). Trends in the percentage of TSCI in hospitalized patients, the percentage of TSCI in hospitalized patients through the orthopaedic departments, and costs were assessed by APC, using the following regression model: $\text{Log}(rt) = a + bt$, where Log denoted the natural logarithm and t was the calendar year (*Salomaa et al., 1992*). The trend (b) was estimated using ordinary regression and $100 \times b$ represented the estimated APC (*Salomaa et al., 1992*).

As exploratory analyses, we calculated trends of the percentages for each included hospital; we also performed two subgroup analyses based on hospital type ("General hospitals" versus "Orthopaedic hospitals") and economic level ("Above the PCDI

283 [Per Capita Disposable Income]" versus "Below the PCDI") (*National Bureau of*
284 *Statistics, 2021*); considering the number of TSCI patients per year admitted by
285 different hospitals varied a lot, we explored the relationship between the number of
286 TSCI per year and the trend of percentages. "Economic level" was divided to
287 "Above the PCDI" (the sum of final consumption expenditure and savings that
288 residents can use, that is, the income that residents can use for free disposal) and
289 "Below the PCDI" according to whether the residents' PCDI in the municipalities or
290 non-municipality cities the hospitals located was higher than the national PCDI. The
291 national PCDI in 2013 (CNY 18 311) was taken as the reference level. All residents'
292 PCDIs come from the National Bureau of Statistics of China (*National Bureau of*
293 *Statistics, 2021*). We hypothesized that the hospitals' TSCI number might influence
294 APC (*Joynt et al., 2011*). Thus, we performed an additional analysis to explore the
295 relationship between the hospitals' TSCI number and APC. The Joinpoint
296 Regression Program, Version 4.8.0.1-April 2020 (Statistical Methodology and
297 Applications Branch, Surveillance Research Program, National Cancer Institute),
298 was used in the calculation of APC (*National Cancer Institute, 2020*). Statistical
299 significance was defined as two-tailed $P < 0.05$. Statistical description of
300 demographic and clinical features, treatment status, and economic burden of TSCI
301 patients was performed using IBM SPSS Statistics Grad Pack 27.0 (IBM SPSS,
302 Chicago, IL, USA). Linear regression and figures drawing were performed using
303 GraphPad Prism version 9.0.2 for Windows (GraphPad Software, San Diego,
304 California USA, www.graphpad.com).

Figure supplement 1. Flow chart of case identification

In the end, a total of 14 754 patients from 37 hospitals in China were included in this study from 2013 to 2018. And the final number of cases included in the "surgery timing", the use of MPSS/MP, and the costs of acute TSCI during hospitalization were shown in the above figure. TSCI=traumatic spinal cord injury. EXCL=excluded. MPSS/MP=methylprednisolone sodium succinate/methylprednisolone.

309 **Table supplement 1. American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade**

AIS grade	Category	Description
A	Complete	No motor or sensory function is preserved in the sacral segments S4–S5
B	Incomplete	Sensory function preserved but not motor function is preserved below the neurological level and includes the sacral segments S4–S5
C	Incomplete	Motor function is preserved below the neurological level, and more than half of key muscles below the neurological level have a muscle grade less than 3
D	Incomplete	Motor function is preserved below the neurological level, and at least half of key muscles below the neurological level have a muscle grade of 3 or more
E	Normal	Motor and sensory function are normal, but still may have abnormal reflexes or other neurologic phenomena ^a .

310 ^a AIS grade E referred to the International standards for neurological classification of spinal cord injury [revised
311 2011] and an article from *J Spinal Cord Med* [Roberts TT, Leonard GR, Cepela DJ. Classifications In Brief:
312 American Spinal Injury Association (ASIA) Impairment Scale. *Clin Orthop Relat Res* 2017;**475**:1499-504.

Results

Epidemiological and Clinical Features

A total of 14 754 TSCI cases were included in this study, with men accounting for 75.3% (n=11 115). The average age was 50.0 years overall, 49.2 years in men and 52.2 years in women. Considering TSCI by occupations, TSCI patients were more likely to be farmers (5 568, 37.7% of 14 754). The top three etiological causes of TSCI, accounting for 83.9% of all causes were: low falls (4 452, 30.2% of 14 754), high falls (4 398, 29.8% of 14 754), and traffic accidents (3 524, 23.9% of 14 754). TSCI occurred most commonly in the cervical segment (8 944, 60.6% of 14 754) and presented most often as incomplete quadriplegia (6 483, 43.9% of 14 754). Almost half of all patients (7 168, 48.6% of 14 754) were classified as AIS grade D on admission, followed by AIS grade A (3 671, 24.9% of 14 754) and AIS grade C (2 512, 17.0% of 14 754). (Table 1)

From 2013 to 2018, the percentage of TSCI in hospitalized patients and the percentage of TSCI in hospitalized patients through the orthopaedic departments did not change significantly overall (APC= -0.5%, 95% CI: -3.0 to 2.1 and APC= -1.6%, 95% CI: -4.9 to 1.8), but the trends varied among individual hospitals (Figure 1 and Figure supplement 2). The percentage of TSCI in hospitalized patients and the percentage of TSCI in hospitalized patients through the orthopaedic departments from general hospitals decreased (APC= -4.2%, 95% CI:

334 -7.2 to -1.0; APC= -5.1%, 95% CI: -8.4 to -1.7) (Table supplement 2). However,
 335 the percentage of TSCI in both hospitalized patients (APC= 8.4%, 95% CI: 3.5 to
 336 13.6) and hospitalized patients through the orthopaedic departments (APC= 7.5%,
 337 95% CI: 2.5 to 12.8) increased when the number of TSCI patients admitted to the
 338 hospital per year was greater than 140 (Figure supplement 3).

339 **Table 1: The epidemiological and clinical features among TSCI patients from 2013 to 2018**

Category	Men	Women	Total
All cases, n (%)	11 115 (75.3)	3 639 (24.7)	14 754 (100.0)
Age, years, mean (SD)	49.2 (14.3)	52.2 (15.3)	50.0 (14.6)
Age groups, n (%)			
15 years~	592 (5.3)	176 (4.8)	768 (5.2)
25 years~	1 284 (11.6)	323 (8.9)	1 607 (10.9)
35 years~	2 017 (18.1)	549 (15.1)	2 566 (17.4)
45 years~	3 139 (28.2)	960 (26.4)	4 099 (27.8)
55 years~	2 510 (22.6)	814 (22.4)	3 324 (22.5)
≥ 65 years	1 573 (14.2)	817 (22.5)	2 390 (16.2)
Occupations, n (%)			
Farmers	4 244 (38.2)	1 324 (36.4)	5 568 (37.7)
Workers	1 504 (13.5)	271 (7.4)	1 775 (12.0)
Retired	656 (5.9)	426 (11.7)	1 082 (7.3)
Office clerks	530 (4.8)	203 (5.6)	733 (5.0)
Students	210 (1.9)	116 (3.2)	326 (2.2)
Self-employed	226 (2.0)	73 (2.0)	299 (2.0)
Civil servants	147 (1.3)	70 (1.9)	217 (1.5)
Drivers	128 (1.2)	28 (0.8)	156 (1.1)
Others ^a	2 845 (25.6)	931 (25.6)	3 776 (25.6)
Missing	625 (5.6)	197 (5.4)	822 (5.6)
Etiological groups, n (%)			
Low falls	3 109 (28.0)	1 343 (36.9)	4 452 (30.2)
High falls	3 500 (31.5)	898 (24.7)	4 398 (29.8)
Traffic accidents	2 650 (23.8)	874 (24.0)	3 524 (23.9)
Struck by falling objects	763 (6.9)	118 (3.2)	881 (6.0)
Sport related injuries	105 (0.9)	61 (1.7)	166 (1.1)
Others ^b	641 (5.8)	243 (6.7)	884 (6.0)
Missing	347 (3.1)	102 (2.8)	449 (3.0)
Level of injury, n (%)			
Cervical	7 109 (64.0)	1 835 (50.4)	8 944 (60.6)
Thoracic	1 695 (15.2)	678 (18.6)	2 373 (16.1)
Lumbosacral	1 981 (17.8)	976 (26.8)	2 957 (20.0)
Multi-site	125 (1.1)	58 (1.6)	188 (1.2)
Cauda equina	21 (0.2)	8 (0.2)	29 (0.2)
Missing	184 (1.7)	84 (2.3)	268 (1.8)
Severity, n (%)			
Complete quadriplegia	1 502 (13.5)	298 (8.2)	1 800 (12.2)
Complete paraplegia	2 248 (20.2)	671 (18.4)	2 919 (19.8)
Incomplete quadriplegia	5 047 (45.4)	1 436 (39.5)	6 483 (43.9)
Incomplete paraplegia	2 131 (19.2)	1 144 (31.4)	3 275 (22.2)
Missing	187 (1.7)	90 (2.5)	277 (1.9)

AIS grade ^c , n (%)			
A	2 933 (26.4)	738 (20.3)	3 671 (24.9)
B	803 (7.2)	206 (5.7)	1 009 (6.8)
C	1 987 (17.9)	525 (14.4)	2 512 (17.0)
D	5 131 (46.2)	2 037 (56.0)	7 168 (48.6)
E	151 (1.4)	97 (2.7)	248 (1.7)
Missing	110 (1.0)	36 (1.0)	146 (1.0)

340 ^a "Others" included "Teachers", "Unemployed" and "Freelances". ^b "Others" included "Injuries
 341 caused by others", "Work related injuries", "Sharp injuries", "Massage related injuries", "Electric
 342 shock injuries", "Gunshot wounds", "Crush injuries", and "Iatrogenic injuries". ^c AIS grade A
 343 represents complete impairment with no motor or sensory function below the level of injury;
 344 grades B–D represent progressively less severe impairment; AIS grade E represents normal
 345 motor and sensory examinations, but still may have abnormal reflexes or other neurologic
 346 phenomena. TSCI=traumatic spinal cord injury. AIS=American Spinal Injury Association (ASIA)
 347 Impairment Scale. SD=standard deviation.

348

349 **Figure 1: Trends in the percentage among TSCI patients from 2013 to 2018**

350 (a) Trends in the percentage of TSCI in hospitalized patients from 23 hospitals, $P = 0.61$. (b) Trends in the percentage of TSCI in hospitalized patients through the
 351 orthopaedic departments from 23 hospitals, $P = 0.25$. TSCI=traumatic spinal cord injury. APC=annual percentage change. 95% CI=95% confidence interval.

Figure supplement 2. Trends in the percentage among TSCI patients of 23 hospitals from 2013 to 2018

(a) Trends in the percentage of TSCI in hospitalized patients of each hospital from 23 hospitals. (b) Trends in the percentage of TSCI in hospitalized patients through the orthopaedic departments of each hospital from 23 hospitals. TSCI=traumatic spinal cord injury. APC=annual percentage change. 95% CI=95% confidence interval.

355 **Table supplement 2. Trends in the percentage of different subgroups among TSCI patients from 2013 to 2018**

Category	2013	2014	2015	2016	2017	2018	APC (95% CI)
TSCI patients/Hospitalized patients							
Hospital type							
General hospital	0.000677437	0.000731737	0.000650481	0.000650376	0.000584477	0.000574924	-4.2 (-7.2, -1.0)
Orthopaedic hospital	0.004146887	0.004100949	0.003582044	0.004432452	0.004789523	0.004711542	3.8 (-2.2, 10.3)
Economic level							
Above the PCDI	0.000764280	0.000854571	0.000837578	0.000813096	0.000837774	0.000864237	1.5 (-1.1, 4.2)
Below the PCDI	0.001961198	0.001901074	0.001352715	0.002064160	0.001701302	0.001434080	-4.1 (-14.5, 7.6)
TSCI patients/Orthopaedic patients							
Hospital type							
General hospital	0.009496961	0.010165120	0.008524518	0.008521055	0.007753479	0.007722081	-5.1 (-8.4, -1.7)
Orthopaedic hospital	0.006207775	0.006087330	0.005567732	0.006757954	0.007892531	0.007828871	6.3 (-0.1, 13.1)
Economic level							
Above the PCDI	0.007594290	0.008133067	0.007529879	0.007149736	0.007625364	0.007885594	-0.2 (-3.3, 3.1)
Below the PCDI	0.010551825	0.010410185	0.006861413	0.010631962	0.008536560	0.007279922	-5.6 (-16.5, 6.8)

356 TSCI=traumatic spinal cord injury. APC=annual percentage change. 95% CI=95% confidence interval. PCDI=per capita disposable income.

357 **Figure supplement 3. The trends of APC in the percentage among TSCI patients from 23 hospitals**

358 (a)The trend of APC in the percentage among TSCI patients in hospitalized patients of different number of TSCI per year. (b) The trend of APC in the percentage
 359 among TSCI patients in hospitalized patients through the orthopaedic departments of different number of TSCI per year. The value of the horizontal axis
 360 represented the annual TSCI patients admitted. The APC corresponding to the points referred to the comprehensive calculation of APC from 2013 to 2018 of all
 361 eligible hospitals whose annual TSCI patients were more than the corresponding number of horizontal axis in 23 hospitals. Shaded regions represent 95%
 362 confidence interval. APC=annual percentage change. TSCI=traumatic spinal cord injury.

Treatment Status

Surgery

10 918 (74.0% of 14 754) patients received surgery after TSCI. The highest surgery rate was found in patients aged 15-24 years (591, 77.0% of 768). For etiological groups, patients with high falls were more likely to receive surgery (3 571, 81.2% of 4 398). Considering the injury level, the highest surgery rate was found in patients with cauda equina (27, 93.1% of 29). Patients with complete paraplegia (2 343, 80.3% of 2 919) and AIS grade B (825, 81.8% of 1 009), had the highest surgery rate considering injury severity and AIS grade, respectively. Among the 10 882 patients who had exact surgery timing, a few (324, 3.0% of 10 882) patients underwent surgery in less than 24 hours. In addition, about a quarter (2 698, 24.8% of 10 882) of patients underwent surgery less than 4.0 days, followed by about a half (5 462, 49.9% of 10 882) within 4.0-11.9 days, and a quarter (2 758, 25.3% of 10 882) more than 11.9 days after injury. (Table 2)

Glucocorticoids

2 084 (14.1% of 14 754) patients were treated with MPSS/MP at a high dose (≥ 500 mg), of which 641 patients (30.8% of 2 084) received it within 8 hours, followed by 1 443 (69.2% of 2 084) at least 8 hours after TSCI. There were more than one third (5 352, 36.3% of 14 754) patients receiving a normal dose of MPSS/MP (< 500 mg), of which most patients (5 012, 93.6% of 5 352) received it continuously and few (340, 6.4% of 5 352) intermittently (Figure 2 and Table

385 supplement 3).

386

387 **Neurotrophic Drugs, Dehydrants and Cathartics**

388 About two thirds (9 590, 65.0% of 14 754) of the patients were treated with
 389 neurotrophic drugs, and the top three categories were GM-1 ganglioside (4 979,
 390 51.9%), mouse nerve growth factor (2 785, 29.0%) and mecobalamin (2 580,
 391 26.9%). Among cases with dehydrants (8 898, 60.3% of 14 754) , mannitol (7 558,
 392 84.9%) was the most commonly used. Glycerin or glycerine enema (1 434, 95.1%)
 393 accounted for the highest proportion of cases with cathartics (1 508, 10.2% of 14
 394 754). (Table supplement 4)

395 **Table 2: The treatment methods and surgery timing among TSCI patients**

Category	Treatment methods		Surgery timing ^a			
	Surgery	Conservative therapies	Section 1	Section 2		
			<24 h	<4.0 d	4.0-11.9 d	>11.9 d
Gender, n (%)						
Men	8 287 (74.6)	2 828 (25.4)	243 (2.9)	2 038 (24.7)	4 196 (50.8)	2 032 (24.6)
Women	2 631 (72.3)	1 008 (27.7)	81 (3.1)	660 (25.2)	1 230 (47.0)	726 (27.8)
Total	10 918 (74.0)	3 836 (26.0)	324 (3.0)	2 698 (24.8)	5 426 (49.9)	2 758 (25.3)
Age groups, n (%)						
15 years~	591 (77.0)	177 (23.0)	26 (4.4)	177 (30.0)	301 (51.0)	112 (19.0)
25 years~	1 214 (75.5)	393 (24.5)	53 (4.4)	375 (30.9)	579 (47.8)	258 (21.3)
35 years~	1 958 (76.3)	608 (23.7)	57 (2.9)	504 (25.9)	981 (50.4)	463 (23.8)
45 years~	3 098 (75.6)	1 001 (24.4)	94 (3.0)	765 (24.8)	1 570 (50.8)	754 (24.4)
55 years~	2 474 (74.4)	850 (25.6)	67 (2.7)	570 (23.1)	1 225 (49.7)	670 (27.2)
≥ 65 years	1 583 (66.2)	807 (33.8)	27 (1.7)	307 (19.5)	770 (48.8)	501 (31.7)
Occupations, n (%)						
Farmers	4 212 (75.6)	1 356 (24.4)	141 (3.4)	1 138 (27.1)	2 083 (49.6)	979 (23.3)
Workers	1 343 (75.7)	432 (24.3)	49 (3.7)	383 (28.6)	672 (50.1)	286 (21.3)
Retired	736 (68.0)	346 (32.0)	10 (1.4)	133 (18.2)	356 (48.6)	243 (33.2)
Office clerks	509 (69.4)	224 (30.6)	26 (5.1)	157 (31.0)	242 (47.8)	107 (21.1)
Students	249 (76.4)	77 (23.6)	13 (5.2)	76 (30.5)	119 (47.8)	54 (21.7)
Self-employed	213 (71.2)	86 (28.8)	8 (3.8)	61 (28.6)	104 (48.8)	48 (22.5)
Civil servants	144 (66.4)	73 (33.6)	2 (1.4)	37 (25.9)	71 (49.7)	35 (24.5)

Drivers	113 (72.4)	43 (27.6)	3 (2.7)	33 (29.2)	56 (49.6)	24 (21.2)
Others ^b	2 749 (72.8)	1 027 (27.2)	62 (2.3)	508 (18.6)	1 372 (50.1)	858 (31.3)
Missing	650 (79.1)	172 (20.9)	10 (1.5)	172 (26.6)	351 (54.3)	124 (19.2)
Etiological groups, n (%)						
Low falls	3 221 (72.3)	1 231 (27.7)	65 (2.0)	641 (20.0)	1 657 (51.7)	909 (28.3)
High falls	3 571 (81.2)	827 (18.8)	139 (3.9)	1 095 (30.7)	1762 (49.4)	707 (19.8)
Traffic accidents	2 489 (70.6)	1 035 (29.4)	65 (2.6)	564 (22.7)	1 221 (49.2)	696 (28.1)
Struck by falling objects	681 (77.3)	200 (22.7)	39 (5.7)	194 (28.6)	320 (47.1)	165 (24.3)
Sport related injuries	103 (62.0)	63 (38.0)	1 (1.0)	20 (19.4)	43 (41.7)	40 (38.8)
Others ^c	552 (62.4)	332 (37.6)	13 (2.4)	92 (16.7)	262 (47.5)	197 (35.8)
Missing	301 (67.0)	148 (33.0)	2 (0.7)	92 (31.0)	161 (54.2)	44 (14.8)
Level of injury, n (%)						
Cervical	6 339 (70.9)	2 605 (29.1)	124 (2.0)	1 203 (19.0)	3 351 (53.0)	1 769 (28.0)
Thoracic	1 905 (80.3)	468 (19.7)	73 (3.9)	547 (28.9)	844 (44.5)	505 (26.6)
Lumbosacral	2 374 (80.3)	583 (19.7)	117 (4.9)	874 (36.9)	1 074 (45.4)	419 (17.7)
Multi-site	161 (88.0)	22 (12.0)	7 (4.4)	48 (30.0)	77 (48.1)	35 (21.9)
Cauda equina	27 (93.1)	2 (6.9)	0 (0.0)	3 (11.1)	18 (66.7)	6 (22.2)
Missing	112 (41.8)	156 (58.2)	3 (2.8)	23 (21.1)	62 (56.9)	24 (22.0)
Severity, n (%)						
Complete quadriplegia	1 274 (70.8)	526 (29.2)	66 (5.2)	395 (31.1)	638 (50.2)	239 (18.8)
Complete paraplegia	2 343 (80.3)	576 (19.7)	130 (5.6)	799 (34.2)	1 023 (43.8)	512 (21.9)
Incomplete quadriplegia	4 590 (70.8)	1 893 (29.2)	46 (1.0)	688 (15.0)	2 486 (54.3)	1 404 (30.7)
Incomplete paraplegia	2 562 (78.2)	713 (21.8)	81 (3.2)	795 (31.1)	1 206 (47.2)	553 (21.7)
Missing	149 (53.8)	128 (46.2)	1 (0.7)	21 (14.6)	73 (50.7)	50 (34.7)
AIS grade ^d , n (%)						
A	2 824 (76.9)	847 (23.1)	157 (5.6)	1 009 (35.8)	1 259 (44.7)	549 (19.5)

B	825 (81.8)	184 (18.2)	48 (5.8)	246 (30.0)	421 (51.3)	154 (18.8)
C	1 937 (77.1)	575 (22.9)	52 (2.7)	397 (20.6)	1 057 (54.8)	476 (24.7)
D	5 117 (71.4)	2 051 (28.6)	62 (1.2)	1 012 (19.8)	2 571 (50.4)	1 521 (29.8)
E	162 (65.3)	86 (34.7)	5 (3.1)	26 (16.1)	96 (59.6)	39 (24.2)
Missing	53 (36.3)	93 (63.7)	0 (0.0)	8 (16.3)	22 (44.9)	19 (38.8)

396 ^a "Surgery timing" represented the time from injury to surgery (h=hours, d=days). ^b "Others" included "Teachers", "Unemployed" and "Freelances". ^c "Others"
 397 included "Injuries caused by others", "Work related injuries", "Sharp injuries", "Massage related injuries", "Electric shock injuries", "Gunshot wounds", "Crush
 398 injuries", and "Iatrogenic injuries". ^d AIS grade A represents complete impairment with no motor or sensory function below the level of injury; grades B–D
 399 represent progressively less severe impairment; AIS grade E represents normal motor and sensory examinations, but still may have abnormal reflexes or other
 400 neurologic phenomena. TSCI=traumatic spinal cord injury. AIS=American Spinal Injury Association (ASIA) Impairment Scale.

401

402 **Figure 2: The use of MPSS/MP among TSCI patients during hospitalization**

403 (a) Use of MPSS/MP at over-instruction dose (≥ 500 mg). (b) Continuous use of MPSS/MP with normal instruction dose (< 500 mg). (c) Intermittent use of

404 MPSS/MP with normal instruction dose (< 500 mg). MPSS/MP=methylprednisolone sodium succinate/methylprednisolone. TSCI=traumatic spinal cord injury.

Table supplement 3. The use of MPSS/MP among TSCI patients during hospitalization

Category ^a	accumulated time≤2 d	3 d ≤accumulated time≤5 d	accumulated time≥6 d	No accumulated time ^b	Total
Use of MPSS/MP at over-instruction dose (≥500 mg)					
≤8 h	--	--	--	641	641
>8 h	--	--	--	1 443	1 443
Total	--	--	--	2 084	2 084
Use of MPSS/MP with normal instruction dose (<500 mg)					
Total					5 352
Continuous use of MPSS/MP with normal instruction dose					
≤1.6 d	495	439	320	--	1 254
1.6-9.0 d	897	923	629	--	2 449
≥9.0 d	505	553	251	--	1 309
Total	1 897	1 915	1 200	--	5 012
Intermittent use of MPSS/MP with normal instruction dose					
≤1.6 d	15	63	75	--	153
1.6-9.0 d	11	62	86	--	159
≥9.0 d	4	9	15	--	28
Total	30	134	176	--	340

^a The rows represented the start time of using MPSS/MP (h=hours, d=days), the columns represented the accumulated time of medication (d=days), and the figures represented the number of TSCI patients. ^b There is no accumulated time about use of MPSS/MP at over-instruction dose (≥500 mg). TSCI=traumatic spinal cord injury. MPSS/MP=methylprednisolone sodium succinate/methylprednisolone.

416 **Table supplement 4. The use of neurotrophic drugs, dehydrants and cathartics among TSCI patients**
 417 **during hospitalization**

Category	Number of patients, n (%) ^a
Neurotrophic drugs	9 590 (65.0)
GM-1 ganglioside	4 979 (51.9)
Mouse nerve growth factor	2 785 (29.0)
Mecobalamin	2 580 (26.9)
Neurotropin	1 927 (20.1)
Cattle encephalon glycoside and ignotin	550 (5.7)
Cobamamide	263 (2.7)
Others ^b	71 (0.7)
Dehydrants	8 898 (60.3)
Mannitol	7 558 (84.9)
Glycerin fructose	1 516 (17.0)
Sodium aescinate	366 (4.1)
Cathartics	1 508 (10.2)
Glycerin or glycerine enemas	1 434 (95.1)
Lactulose oral solution	128 (8.5)
Maren soft capsule	25 (1.7)

418 ^aThe overall use rate of neurotrophic drugs, dehydrants and cathartics was calculated by the proportion among
 419 TSCI patients. The utilization rate of each drug was calculated by the proportion among patients who used
 420 neurotrophic drugs, dehydrants or cathartics. ^b"others" included "Muscular amino acids and nucleosides" and/or
 421 "Deproteinized calf blood extractive". TSCI=traumatic spinal cord injury.

Economic Burden and length of hospital stay

The mean total costs among the 10 945 acute TSCI cases were CNY ¥ 71.0k (USD \$ 11.5k), with daily costs of ¥ 4.4k (\$ 0.7k). Both total and daily costs decreased gradually with age. Total costs were highest in students (¥ 79.6k, \$ 12.9k) but daily costs were highest in workers (¥ 4.4k, \$ 0.7k) considering occupations categories. Total costs were highest in patients struck by falling objects (¥ 95.9k, \$ 15.5k) while daily costs was highest in high falls (¥ 4.9k, \$ 0.8k) considering etiological groups. Total and daily costs were highest in cauda equina (¥ 94.1k, \$ 15.2k; ¥ 5.1k, \$ 0.8k) considering injury level. Both total and daily costs increased with the increasing of AIS grade (E to A). The average length of hospital stay was 19.9 (SD= 26.2) days. (Tables 3 and Table supplement 5)

Between 2013 and 2018, the total costs for acute TSCI decreased (APC= -4.8%, 95% CI: -6.2 to -3.4). The daily costs did not change significantly (APC= 0.5%, 95% CI: -1.2 to 2.2), the same for both men (APC= 0.3%, 95% CI: -1.8 to 2.4) and women (APC= 1.7%, 95% CI: -1.6 to 5.2). The daily costs of each age group did not change significantly, except for patients aged ≥ 65 years with a increase (APC= 2.9%, 95% CI: 0.1 to 5.9). In addition, the average length of hospital stay decreased (APC= -4.5, 95% CI: -8.1 to -0.6). (Table supplement 5 and Table supplement 6)

441 **Table 3: The costs among acute TSCI patients during hospitalization**

Category	Number of patients, n	Total costs	Daily costs
		(CNY/USD, thousand)	(CNY/USD, thousand)
		Mean (SD)	Mean (SD)
Gender			
Men	8 304	¥ 73.6 (72.3), \$ 11.9 (11.7)	¥ 4.4 (3.4), \$ 0.7 (0.6)
Women	2 641	¥ 62.6 (65.1), \$ 10.1 (10.5)	¥ 4.2 (3.5), \$ 0.7 (0.6)
Total	10 945	¥ 71.0 (70.8), \$ 11.5 (11.4)	¥ 4.4 (3.4), \$ 0.7 (0.6)
Age groups			
15 years~	602	¥ 83.5 (100.9), \$ 13.5 (16.3)	¥ 4.6 (3.5), \$ 0.7 (0.6)
25 years~	1 223	¥ 78.5 (70.9), \$ 12.7 (11.4)	¥ 4.5 (3.5), \$ 0.7 (0.6)
35 years~	1 928	¥ 75.6 (79.7), \$ 12.2 (12.9)	¥ 4.5 (3.4), \$ 0.7 (0.5)
45 years~	3 073	¥ 73.1 (65.2), \$ 11.8 (10.5)	¥ 4.4 (3.5), \$ 0.7 (0.6)
55 years~	2 439	¥ 65.9 (58.5), \$ 10.6 (9.4)	¥ 4.2 (3.5), \$ 0.7 (0.6)
≥ 65 years	1 680	¥ 59.0 (70.7), \$ 9.5 (11.4)	¥ 4.1 (3.2), \$ 0.7 (0.6)
Occupations			
Farmers	4 215	¥ 64.7 (54.6), \$ 10.4 (8.8)	¥ 4.3 (3.3), \$ 0.7 (0.5)
Workers	1 387	¥ 79.0 (75.7), \$ 12.7 (12.2)	¥ 4.4 (4.0), \$ 0.7 (0.6)
Retired	769	¥ 55.5 (52.5), \$ 9.0 (8.5)	¥ 4.0 (3.1), \$ 0.6 (0.5)
Office clerks	541	¥ 70.6 (72.7), \$ 11.4 (11.7)	¥ 4.4 (4.1), \$ 0.7 (0.7)
Students	282	¥ 79.6 (124.4), \$ 12.9 (20.1)	¥ 4.2 (3.8), \$ 0.7 (0.6)
Self-employed	229	¥ 61.3 (52.3), \$ 10.7 (9.1)	¥ 3.8 (2.9), \$ 0.6 (0.5)
Civil servants	179	¥ 63.1 (60.2), \$ 9.9 (8.4)	¥ 3.9 (3.9), \$ 0.6 (0.6)
Drivers	134	¥ 74.5 (97.0), \$ 12.0 (15.7)	¥ 3.8 (2.7), \$ 0.6 (0.4)
Others ^a	2 759	¥ 79.0 (85.3), \$ 12.8 (13.8)	¥ 4.5 (3.2), \$ 0.7 (0.5)
Missing	450	¥ 83.9 (60.7), \$ 13.5 (9.8)	¥ 5.6 (3.4), \$ 0.9 (0.5)
Etiological groups			
Low falls	3 260	¥ 54.7 (49.2), \$ 8.8 (8.0)	¥ 3.9 (3.3), \$ 0.6 (0.5)
High falls	3 459	¥ 81.2 (73.6), \$ 13.1 (11.9)	¥ 4.9 (3.5), \$ 0.8 (0.6)
Traffic accidents	2 705	¥ 73.8 (74.5), \$ 11.9 (12.0)	¥ 4.3 (3.3), \$ 0.7 (0.5)
Struck by falling objects	657	¥ 95.9 (110.8), \$ 15.5 (17.9)	¥ 4.8 (4.0), \$ 0.8 (0.6)
Sport related injuries	117	¥ 42.4 (42.0), \$ 6.8 (6.8)	¥ 4.0 (4.2), \$ 0.7 (0.7)
Others ^b	573	¥ 64.4 (68.5), \$ 10.4 (11.1)	¥ 3.6 (2.9), \$ 0.6 (0.5)
Missing	174	¥ 74.2 (51.3), \$ 12.0 (8.3)	¥ 5.3 (3.3), \$ 0.9 (0.5)
Level of injury			
Cervical	6 594	¥ 65.9 (68.4), \$ 10.6 (11.1)	¥ 4.2 (3.3), \$ 0.7 (0.5)
Thoracic	1 783	¥ 94.1 (90.5), \$ 15.2 (14.6)	¥ 5.0 (3.8), \$ 0.8 (0.6)
Lumbosacral	2 242	¥ 68.2 (56.9), \$ 11.0 (9.2)	¥ 4.4 (3.7), \$ 0.7 (0.6)
Multi-site	132	¥ 72.4 (43.2), \$ 11.7 (7.0)	¥ 5.0 (2.7), \$ 0.8 (0.4)
Cauda equina	37	¥ 94.1 (39.6), \$ 15.2 (6.4)	¥ 5.1 (1.7), \$ 0.8 (0.3)
Missing	157	¥ 52.5 (59.1), \$ 8.5 (9.5)	¥ 3.5 (2.7), \$ 0.6 (0.4)
Severity			
Complete quadriplegia	1 417	¥ 92.5 (102.0), \$ 14.9 (16.5)	¥ 4.8 (3.3), \$ 0.8 (0.5)

Complete paraplegia	2 248	¥ 93.0 (89.2), \$ 15.0 (14.4)	¥ 5.1 (4.2), \$ 0.8 (0.7)
Incomplete quadriplegia	4 702	¥ 58.6 (50.7), \$ 9.5 (8.2)	¥ 4.0 (3.2), \$ 0.6 (0.5)
Incomplete paraplegia	2 467	¥ 62.7 (53.9), \$ 10.1 (8.7)	¥ 4.2 (3.0), \$ 0.7 (0.5)
Missing	111	¥ 57.1 (51.2), \$ 9.2 (8.3)	¥ 3.7 (2.9), \$ 0.6 (0.5)
AIS grade ^d			
A	2 958	¥ 96.4 (101.5), \$ 15.6 (16.4)	¥ 5.1 (4.0), \$ 0.8 (0.6)
B	731	¥ 92.5 (71.7), \$ 14.9 (11.6)	¥ 5.1 (3.8), \$ 0.8 (0.6)
C	1 831	¥ 75.9 (56.2), \$ 12.3 (9.1)	¥ 4.5 (3.0), \$ 0.7 (0.5)
D	5 208	¥ 52.4 (43.5), \$ 8.5 (7.0)	¥ 3.8 (3.1), \$ 0.6 (0.5)
E	171	¥ 49.5 (53.6), \$ 8.0 (8.7)	¥ 3.3 (3.0), \$ 0.5 (0.5)
Missing	46	¥ 70.4 (76.7), \$ 11.4 (12.4)	¥ 4.1 (2.3), \$ 0.7 (0.4)

442 ^a "Others" included "Teachers", "Unemployed" and "Freelances". ^b "Others" included "Injuries caused by others",
 443 "Work related injuries", "Sharp injuries", "Massage related injuries", "Electric shock injuries", "Gunshot
 444 wounds", "Crush injuries", and "Iatrogenic injuries". ^c AIS grade A represents complete impairment with no
 445 motor or sensory function below the level of injury; grades B–D represent progressively less severe impairment;
 446 AIS grade E represents normal motor and sensory examinations, but still may have abnormal reflexes or other
 447 neurologic phenomena. TSCI=traumatic spinal cord injury. AIS=American Spinal Injury Association (ASIA)
 448 Impairment Scale. CNY=Chinese Yuan. USD=USA dollar. SD=standard deviation.

49 **Table supplement 5. Trends in the length of hospital stay among acute TSCI patients from 2013 to 2018^a**

Category	Overall	2013	2014	2015	2016	2017	2018	APC (95% CI)
Gender, Mean (SD)								
Men	20.4 (27.1)	21.9 (20.7)	23.1 (40.1)	20.1 (23.7)	21.2 (25.8)	19.6 (28.6)	17.7 (17.9)	-4.2 (-7.5, -0.8)
Women	18.5 (23.2)	19.4 (16.8)	20.1 (19.5)	20.4 (26.4)	19.9 (25.4)	18.1 (30.3)	14.6 (15.0)	-4.9 (-10.7, 1.3)
Total	19.9 (26.2)	21.3 (19.8)	22.4 (36.5)	20.1 (24.3)	20.9 (25.7)	19.3 (29.0)	16.8 (17.2)	-4.5 (-8.1, -0.6)
Age groups, Mean (SD)								
15 years~	22.4 (31.6)	20.9 (14.9)	25.0 (26.2)	20.5 (24.0)	23.2 (22.8)	26.5 (64.6)	19.0 (16.2)	-0.5 (-9.5, 9.3)
25 years~	21.5 (25.3)	25.8 (29.4)	25.2 (29.8)	21.9 (30.2)	20.2 (19.1)	19.6 (22.2)	18.8 (21.6)	-6.7 (-8.8, -4.5)
35 years~	21.1 (35.1)	21.8 (22.2)	24.0 (62.8)	21.6 (28.7)	21.0 (27.6)	18.7 (21.8)	19.4 (23.7)	-3.8 (-7.4, -0.1)
45 years~	20.9 (25.9)	20.6 (14.7)	22.5 (23.9)	22.1 (27.4)	21.8 (29.0)	20.8 (32.4)	18.0 (18.5)	-2.6 (-7.1, 2.2)
55 years~	18.6 (19.9)	20.7 (19.2)	21.7 (27.6)	16.8 (14.5)	20.6 (22.5)	16.7 (20.0)	16.2 (12.5)	-5.0 (-11.1, 1.5)
≥ 65 years	16.9 (20.3)	19.3 (19.1)	16.9 (14.6)	18.1 (17.6)	19.5 (26.6)	18.2 (27.1)	12.5 (9.5)	-5.2 (-14.0, 4.5)

50 ^aLength of hospital stay was measured in days.

51 **Table supplement 6. Trends in the costs among acute TSCI patients from 2013 to 2018**

Category	2013	2014	2015	2016	2017	2018	APC (95% CI)
Total costs (CNY ¥, thousand), Mean (SD)							
Gender							
Men	85.0 (79.8)	81.2 (85.1)	72.7 (62.2)	72.3 (64.3)	68.4 (75.4)	68.0 (67.3)	-4.6 (-6.5, -2.6)
Women	67.8 (58.4)	72.9 (108.0)	67.6 (69.3)	62.0 (54.1)	57.9 (47.1)	54.2 (46.3)	-5.3 (-8.4, -2.1)
Total	80.6 (75.3)	79.4 (90.8)	71.5 (63.8)	69.8 (62.2)	65.8 (69.7)	64.4 (62.8)	-4.8 (-6.2, -3.4)
Age groups							
15 years~	84.1 (58.9)	104.8 (201.5)	80.4 (70.1)	75.6 (51.9)	80.0 (96.2)	78.3 (59.8)	-3.5 (-10.2, 3.8)
25 years~	96.3 (100.6)	95.5 (93.9)	71.2 (66.4)	75.8 (61.4)	73.5 (56.8)	68.8 (46.1)	-6.6 (-11.8, -1.2)
35 years~	83.5 (90.1)	81.1 (98.9)	72.8 (53.8)	75.4 (70.7)	69.3 (51.4)	72.3 (97.6)	-3.3 (-5.8, -0.6)
45 years~	86.1 (68.6)	75.3 (61.9)	78.3 (68.8)	69.9 (69.1)	67.7 (61.4)	68.9 (61.4)	-4.3 (-7.2, -1.4)
55 years~	73.3 (65.7)	76.0 (74.8)	64.3 (56.2)	68.3 (53.7)	57.0 (46.4)	61.2 (52.8)	-4.8 (-8.9, -0.4)
≥ 65 years	61.6 (57.1)	63.6 (64.7)	63.7 (68.4)	59.0 (50.6)	62.4 (110.9)	50.3 (44.3)	-3.2 (-7.8, 1.6)
Daily costs (CNY ¥, thousand), Mean (SD)							
Gender							
Men	4.5 (3.4)	4.3 (3.4)	4.4 (3.1)	4.2 (2.8)	4.5 (3.9)	4.5 (3.6)	0.3 (-1.8, 2.4)
Women	3.9 (3.6)	4.4 (3.9)	4.2 (3.5)	4.0 (3.3)	4.3 (3.3)	4.5 (3.5)	1.7 (-1.6, 5.2)
Total	4.4 (3.5)	4.3 (3.5)	4.3 (3.2)	4.2 (2.9)	4.4 (3.8)	4.5 (3.6)	0.5 (-1.2, 2.2)
Age groups							
15 years~	4.4 (3.0)	5.1 (5.6)	4.3 (2.6)	4.3 (3.2)	4.6 (3.0)	4.8 (3.0)	0.4 (-4.6, 5.6)
25 years~	4.6 (3.6)	4.6 (3.4)	4.4 (3.8)	4.3 (2.8)	4.7 (4.7)	4.5 (2.7)	-0.2 (-2.6, 2.2)
35 years~	4.6 (4.2)	4.5 (3.8)	4.4 (2.9)	4.5 (3.2)	4.7 (3.2)	4.3 (2.8)	-0.5 (-2.7, 1.7)
45 years~	4.6 (3.2)	4.3 (3.4)	4.6 (3.7)	4.1 (2.6)	4.5 (4.5)	4.5 (3.0)	-0.3 (-3.5, 3.1)
55 years~	4.2 (2.9)	4.2 (3.1)	4.1 (2.7)	4.1 (3.2)	4.2 (3.3)	4.5 (4.9)	1.0 (-1.1, 3.2)
≥ 65 years	3.8 (3.9)	3.9 (2.9)	4.0 (3.1)	3.8 (2.5)	4.2 (3.1)	4.5 (3.5)	2.9 (0.1, 5.9)

52 TSCI=traumatic spinal cord injury. APC=annual percentage change. 95% CI=95% confidence interval. CNY=Chinese Yuan. SD=standard deviatio

Discussion

To our knowledge, this is the first national-level study of the epidemiological and clinical features, treatment status and economic burden of TSCI in China. The study was a retrospective multicentre hospital-based study of TSCI from 2013 to 2018. We found that the percentage of TSCI in hospitalized patients and the percentage of TSCI in hospitalized patients through the orthopaedic departments did not change significantly overall, but the percentage of TSCI in both hospitalized patients and hospitalized patients through the orthopaedic departments increased when the number of TSCI per year was greater than 140. We described the treatment status with regard to: surgery, MPSS/MP, neurotrophic drugs, dehydrants and cathartics in detail. The total costs for acute TSCI decreased, while the daily costs did not change significantly.

The epidemiological features, such as gender (male: 75.3%) and average age (50.0 years) were consistent with other previous area studies of TSCI in China (*Yuan et al., 2018*). Our results showed that TSCI patients were more likely to be farmers (37.7%), which was different from the epidemiological studies in Turkey and Mexico (*Güzelküçük et al., 2015; Zárate-Kalfópulos et al., 2016*). The higher number of farmers suffering TSCI in China compared with other countries might reflect the type of work farmers in China are undertaking, including high-risk construction, which increases the risk of falls from elevated heights, which made up 29.8% of all TSCI (*National Bureau of Statistics, 2021*).

From 2013 to 2018, the percentage of TSCI in hospitalized patients and the percentage of TSCI in hospitalized patients through the orthopaedic departments did not change significantly overall. This finding was similar with the trend of age-standardized incidence rates of spinal cord injury in China reported in the GBD study (*GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators, 2019*). The percentage of TSCI in both hospitalized patients and hospitalized patients through the orthopaedic departments increased when the number of TSCI per year was greater than 140, which might reflect a changing trend in China of TSCI patients being treated in hospitals with more TSCI expertise. Transferring patients who suffer a TSCI into hospitals with speciality in TSCI is likely to improve the quality of the patients care, and might also help reduce the burden on the large non-specialist hospitals. In China, the over-burdening of the large non-specialist hospitals has prevented optimal care from being provided for TSCI, such as early treatment (*National Health Commission of the People's Republic of China, 2019*).

One of the recommended early treatment for TSCI is surgery (*Robert R Hansebout, 2021*), and a recent pooled analysis including 1 548 patients showed that surgery decompression within 24 hours of acute spinal cord injury was associated with improved sensorimotor recovery (*Badhiwala et al., 2021*). In our study, about 3.0% of 10 882 patients underwent surgery received surgery less than 24 hours after injury. Irrespective of the preference of clinicians on the use of early surgery, most hospitals do not have capacity to complete early

surgery of TSCI because they lacked experienced surgeons, imaging and laboratory equipment, and preanesthetic assessments (*Thompson et al., 2018*).

Another key area of managing TSCI is pharmacological interventions. Current pharmacological treatment principally relies on the off-label use of MPSS/MP, which remains contentious (*Robert R Hansebout, 2021*). Based upon the available evidence, the American Association of Neurological Surgeons and the Congress of Neurological Surgeons (AANS/CNS) stated that "administration of methylprednisolone (MP) for the treatment of acute spinal cord injury is not recommended" in 2013, and concluded that "there is insufficient evidence to make a recommendation" of using MP for treatment of patients with thoracic and lumbar fractures and spinal cord injury in 2019 (*Hurlbert et al., 2013; Arnold et al., 2019*). AOSpine organization on the other hand suggested a high-dose of MPSS/MP within 8 hours of acute SCI as a treatment option in their 2017 guideline (*Fehlings et al., 2017*). A retrospective population-based cohort study showed that 61.5% (rang from 40.7 to 75.7) patients in South Korea between 2007 and 2017 received high-dose MPSS/MP within 8 hours of acute spinal cord injury (*Choi et al., 2020*). In our study, we used 500mg of MPSS/MP as a threshold, based on the user guide, and found that 2 084 (14.1% of 14 754) TSCI patients were treated with a MPSS/MP of ≥ 500 mg, with only 641 (4.3% of 14 754) patients receiving it within 8 hours. The low rates of MPSS/MP use might reflect the conflicting recommendations in guidelines, the ongoing controversy in clinical management, limited resources in Chinese hospitals or a lack of awareness of best practice among the health

professionals treating TSCI patients (*Robert R Hansebout, 2021; Arnold et al., 2019*). Future high-quality randomized controlled trials or comprehensive observational studies based on large-scale electronic medical records are therefore needed, to explore the benefit of glucocorticoids treatment and help inform clinical care (*Liu et al., 2019*).

In addition to the low rates of early surgery and glucocorticoids use identified in this study, there was also found to be common use of treatments not part of recommended usual care in treating TSCI, such as neurotrophic drugs, dehydrants, and cathartics. Moreover, the AANS/CNS stated that "administration of GM-1 ganglioside (Sygen) for the treatment of acute SCI was not recommended" in 2013 and "there is insufficient evidence to make a recommendation" to use GM-1 ganglioside for patients with thoracic and lumbar fractures and spinal cord injury in 2019 (*Hurlbert et al., 2013; Arnold et al., 2019*). In this study, 9 590 (65.0%) patients used neurotrophic drugs, of which 4 979 (51.9%) patients used GM-1 ganglioside. The high rates of neurotrophic drugs in China might reflect the insufficient high-quality evidence to recommend for or against it.

Considering the costs related to acute TSCI, we found that the total costs on average were CNY ¥ 71.0k (USD \$ 11.5k), which was 3.9 times that of disposable income per capita of 2013 (¥ 18.3k) (from the National Bureau of Statistics of the People's Republic of China) in China (*National Bureau of Statistics, 2021*). These costs are not only a large burden for patients and their families but also for the health providers. China has the largest number of

spinal cord injuries (3 739 610) and the second highest number of new cases (98 226) in 2016 worldwide based on the 2016 GBD study (*GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators, 2019*). The total costs decreased but the daily costs did not change significantly during the same period, which was consistent with the reduction in the average length of hospital stay. On the one hand, the cause of hospital stay reduction might be due to most hospitals improving the diagnosis and treatment or/and simplifying the process in and out of the hospital in China (*National Health Commission of the People's Republic of China, 2019*). On the other hand, it might be a reflection of patients leaving the hospital earlier to save money, rather than due to improved care leading to early discharge. The early discharge from hospital might also lead to deep wound infection, wound dehiscence, and deep venous thrombosis (*Otero et al., 2016*).

Although this study was the largest known study of TSCI cases in China, it still possessed some limitations. First, it was not a population-based design, which meant that we could not calculate the incidence and prevalence rates of TSCI from the whole population. Another limitation in this study was the representative of sample. Although many hospitals were chosen across China, we did not use strict sampling rule so that our study is not a national representative one. Third, we only described the use of MPSS/MP in the part of glucocorticoids usage, without hydrocortisone and dexamethasone, due to the uncertainty whether other glucocorticoids were used in the treatment of TSCI itself.

Conclusion

This study revealed the epidemiological and clinical features of TSCI that occurred in China from 2013 to 2018. We found that the percentage of TSCI in hospitalized patients and the percentage of TSCI in hospitalized patients through the orthopaedic departments did not change significantly, but both these percentages increased when the number of TSCI per year was greater than 140. We described the treatment status about surgery, MPSS/MP, neurotrophic drugs, dehydrants and cathartics. The total costs for TSCI decreased, but the daily costs did not change significantly. Further studies should focus on assessing the efficacy and safety of current treatment strategies.

Acknowledgments

We thank Ping Yu from Library of Tianjin Medical University for developing the search strategies for TSCI. We thank Jiaxiao Shi, Xuanhao Fu, Wenxiang Li, Shibo Zhu, Linlin Shi, Weixiao Liu, Shenghui Shang, Shiyang Yuan, Guowang Li, Chao Sun, Huiquan Duan, Siyue Jia, Chaoyu Wang, Ziqian Xiang, Chao Li, Yigang Lv and Hao Yu for data collection. We thank Wei Li from Zhengzhou Orthopaedics Hospital, Yi Zhang from The First Affiliated Hospital of Zhengzhou University, Dantong Sun from The Eighth People's Hospital of Shenyang, Zanjing Zhai from Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Bo Wu from Shenyang Orthopaedics Hospital, Xueming Chen from Beijing Luhe Hospital, Affiliated to Capital Medical University, Xianze Sun from

The Third Hospital of Shijiazhuang, Zaixian Long from Xiushan People's Hospital, Si Yin from The First Affiliated Hospital of Xi'an Jiaotong University, Shenglin Zhang from Jinhu County People's Hospital. Zhihua Wang from People's Hospital of Wuzhi County. Wei Ma and Xing Dai from Hanyin county people's hospital, Jidong Li from Hospital of Jingxing County, Dazhi Yang from Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Jiancheng Zeng from West China Hospital, Sichuan University, and Deguo Teng from The Second People's Hospital of Shifang for data management.

Declaration of interests

We declare no conflicts of interests.

Contributors

SQF and HXZ designed the study and obtained funding. HXZ, YFL, LXC, YK and JHW did data analysis and the preparation of the manuscript. LL, ZWC and CZ did figures design. All authors read and approved the final version.

Funding

National Key Research and Development Project of Stem Cell and Transformation Research (2019YFA0112100). This funding organization has no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data sharing

The data are available from the corresponding author on reasonable request.

References

- Ahuja CS, Wilson JR, Nori S, Kotter M, Druschel C, Curt A, Fehlings MG. 2017. Traumatic spinal cord injury. *Nature reviews. Disease primers* **3**:17018. doi: 10.1038/nrdp.2017.18, PMID: 28447605
- Arnold PM, Anderson PA, Chi JH, Dailey AT, Dhall SS, Eichholz KM, Harrop JS, Hoh DJ, Qureshi S, Rabb CH, Raksin PB, Kaiser MG, O'Toole JE. 2019. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Evaluation and Treatment of Patients With Thoracolumbar Spine Trauma: Pharmacological Treatment. *Neurosurgery* **84**:E36-36E38. doi: 10.1093/neuros/nyy371, PMID: 30202962
- Badhiwala JH, Wilson JR, Fehlings MG. 2019. Global burden of traumatic brain and spinal cord injury. *The Lancet. Neurology* **18**:24-25. doi: 10.1016/S1474-4422(18)30444-7, PMID: 30497967
- Badhiwala JH, Wilson JR, Witiw CD, Harrop JS, Vaccaro AR, Aarabi B, Grossman RG, Geisler FH, Fehlings MG. 2021. The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data. *The Lancet. Neurology* **20**:117-126. doi: 10.1016/S1474-4422(20)30406-3, PMID: 33357514
- Choi SH, Sung CH, Heo DR, Jeong SY, Kang CN. 2020. Incidence of acute spinal cord injury and associated complications of methylprednisolone therapy: a national population-based study in South Korea. *Spinal cord* **58**:232-237. doi: 10.1038/s41393-019-0357-2, PMID: 31527724
- DXY Drugs Information. 2021. Medication Instructions for Methylprednisolone Sodium Succinate for Injection. *Available at: http://drugs.dxy.cn/drug/93535.htm. Accessed March 23,2021* .
- Fehlings MG, Wilson JR, Tetreault LA, Aarabi B, Anderson P, Arnold PM, Brodke DS, Burns AS, Chiba K, Dettori JR, Furlan JC, Hawryluk G, Holly LT, Howley S, Jeji T, Kalsi-Ryan S, Kotter M, Kurpad S, Kwon BK, Marino RJ, Martin AR, Massicotte E, Merli G, Middleton JW, Nakashima H, Nagoshi N, Palmieri K, Skelly AC, Singh A, Tsai EC, Vaccaro A, Yee A, Harrop JS. 2017. A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations

618 on the Use of Methylprednisolone Sodium Succinate. *Global spine journal* **7**:203S-211S. doi:

619 10.1177/2192568217703085, PMID: 29164025

620 GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. 2019. Global, regional, and national burden of

621 traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease

622 Study 2016. *The Lancet. Neurology* **18**:56-87. doi: 10.1016/S1474-4422(18)30415-0, PMID: 30497965

623 Gordon LG. 2020. China guidelines for pharmacoeconomic evaluations (2020). China Market Press. Beijing. 117-119.

624 Gross-Hemmi MH, Post MW, Ehrmann C, Fekete C, Hasnan N, Middleton JW, Reinhardt JD, Strøm V, Stucki G, International

625 Spinal Cord Injury Community Survey (InSCI) Group. 2017. Study Protocol of the International Spinal Cord Injury

626 (InSCI) Community Survey. *American journal of physical medicine & rehabilitation* **96**:S23-23S34. doi:

627 10.1097/PHM.0000000000000647, PMID: 28059876

628 Güzelkütük Ü, Kesikburun S, Demir Y, Aras B, Özyörük E, Yılmaz B, Tan AK. 2015. Demographic and clinical characteristics of

629 patients with traumatic cervical spinal cord injury: a Turkish hospital-based study. *Spinal cord* **53**:441-445. doi:

630 10.1038/sc.2014.211, PMID: 25487242

631 Harrell Jr FE. 2015. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and

632 survival analysis. Springer.

633 Hurlbert RJ, Hadley MN, Walters BC, Aarabi B, Dhall SS, Gelb DE, Rozzelle CJ, Ryken TC, Theodore N. 2013. Pharmacological

634 therapy for acute spinal cord injury. *Neurosurgery* **72 Suppl 2**:93-105. doi: 10.1227/NEU.0b013e31827765c6, PMID:

635 23417182

636 Institute for Health Metrics and Evaluation. 2021. Global Health Data Exchange. Available at:

637 <http://ghdx.healthdata.org/gbd-results-tool>. Accessed March 23, 2021.

638 Joynt KE, Orav EJ, Jha AK. 2011. The association between hospital volume and processes, outcomes, and costs of care for
639 congestive heart failure. *Annals of internal medicine* **154**:94-102. doi: 10.7326/0003-4819-154-2-201101180-00008,
640 PMID: 21242366

641 Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, Johansen M, Jones L, Krassioukov A, Mulcahey
642 MJ, Schmidt-Read M, Waring W. 2011. International standards for neurological classification of spinal cord injury
643 (revised 2011). *The journal of spinal cord medicine* **34**:535-546. doi: 10.1179/204577211X13207446293695, PMID:
644 22330108

645 Liu Z, Yang Y, He L, Pang M, Luo C, Liu B, Rong L. 2019. High-dose methylprednisolone for acute traumatic spinal cord injury:
646 A meta-analysis. *Neurology* **93**:e841-841e850. doi: 10.1212/WNL.0000000000007998, PMID: 31358617

647 National Bureau of Statistics. 2021. Available at: <https://data.stats.gov.cn>. Accessed March 23, 2021 .

648 National Bureau of Statistics. 2021. National Migrant Workers Monitoring Survey Report in 2013. Available at:
649 http://www.stats.gov.cn/tjsj/zxfb/201405/t20140512_551585.html. Accessed March 24, 2021. .

650 National Cancer Institute. 2020. Joinpoint Regression Program. Available at: <https://surveillance.cancer.gov/joinpoint/>
651 Accessed April 2020 .

652 National Health Commission of the People's Republic of China. 2019. National Report on the Services, Quality and Safety in
653 medical care system (2018). Science and Technical Literature Press. Beijing.

654 National Spinal Cord Injury Statistical Center. 2016. Spinal Cord Injury (SCI) Facts and Figures at a Glance. *The journal of*
655 *spinal cord medicine* **39**:370-371. doi: 10.1080/10790268.2016.1177348, PMID: 27193177

656 Otero JE, Gholson JJ, Pugely AJ, Gao Y, Bedard NA, Callaghan JJ. 2016. Length of Hospitalization After Joint Arthroplasty:
657 Does Early Discharge Affect Complications and Readmission Rates. *The Journal of arthroplasty* **31**:2714-2725. doi:
658 10.1016/j.arth.2016.07.026, PMID: 27600301

- 659 Robert R Hansebout EK. 2021. Acute traumatic spinal cord injury. *Janet LW, ed. UpToDate. Waltham, MA: UpToDate Inc.*
- 660 <https://www.uptodate.com> (Accessed on March 23, 2021.) .
- 661 Roberts TT, Leonard GR, Cepela DJ. 2017. Classifications In Brief: American Spinal Injury Association (ASIA) Impairment Scale.
- 662 *Clinical orthopaedics and related research* **475**:1499-1504. doi: 10.1007/s11999-016-5133-4, PMID: 27815685
- 663 Salomaa V, Arstila M, Kaarsalo E, Ketonen M, Kuulasmaa K, Lehto S, Miettinen H, Mustaniemi H, Niemelä M, Palomäki P.
- 664 1992. Trends in the incidence of and mortality from coronary heart disease in Finland, 1983-1988. *American journal*
- 665 *of epidemiology* **136**:1303-1315. doi: 10.1093/oxfordjournals.aje.a116442, PMID: 1488958
- 666 Selvarajah S, Hammond ER, Haider AH, Abularrage CJ, Becker D, Dhiman N, Hyder O, Gupta D, Black JH 3rd, Schneider EB.
- 667 2014. The burden of acute traumatic spinal cord injury among adults in the united states: an update. *Journal of*
- 668 *neurotrauma* **31**:228-238. doi: 10.1089/neu.2013.3098, PMID: 24138672
- 669 Thompson C, Feldman DE, Mac-Thiong JM. 2018. Surgical management of patients following traumatic spinal cord injury:
- 670 Identifying barriers to early surgery in a specialized spinal cord injury center. *The journal of spinal cord medicine*
- 671 **41**:142-148. doi: 10.1080/10790268.2016.1165448, PMID: 27077578
- 672 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. 2007. The Strengthening the
- 673 Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational
- 674 studies. *Annals of internal medicine* **147**:573-577. doi: 10.7326/0003-4819-147-8-200710160-00010, PMID:
- 675 17938396
- 676 Yuan S, Shi Z, Cao F, Li J, Feng S. 2018. Epidemiological Features of Spinal Cord Injury in China: A Systematic Review.
- 677 *Frontiers in neurology* **9**:683. doi: 10.3389/fneur.2018.00683, PMID: 30186222

- 678 Zárate-Kalfópulos B, Jiménez-González A, Reyes-Sánchez A, Robles-Ortiz R, Cabrera-Aldana EE, Rosales-Olivarez LM. 2016.
- 679 Demographic and clinical characteristics of patients with spinal cord injury: a single hospital-based study. *Spinal cord*
- 680 54:1016-1019. doi: 10.1038/sc.2016.41, PMID: 27067655

Supplementary Information:

Epidemiological and Clinical Features, Treatment Status, and Economic Burden of Traumatic Spinal Cord Injury in China

*Corresponding Author: Shiqing Feng, International Science and Technology Cooperation Base of Spinal Cord Injury, Department of orthopaedics, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin Key Laboratory of Spine and Spinal Cord, Tianjin, 300052, P.R. China; Department of orthopaedics, Qilu Hospital, Shandong University Centre for orthopaedics, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China. Tel/fax: +8602288366139. sqfeng@tmu.edu.cn.

Section

Supplemental methods

Figure supplement 1. Flow chart of case identification

Table supplement 1. American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade

Supplemental results

Figure supplement 2. Trends in the percentage among TSCI patients of 23 hospitals from 2013 to 2018

Table supplement 2. Trends in the percentage of different subgroups among TSCI patients from 2013 to 2018

Figure supplement 3. The trends of APC in the percentage among TSCI patients from 23 hospitals

Table supplement 3. The use of MPSS/MP among TSCI patients during hospitalization

Table supplement 4. The use of neurotrophic drugs, dehydrants and cathartics among TSCI patients during hospitalization

Table supplement 5. Trends in the length of hospital stay among acute TSCI patients from 2013 to 2018

Table supplement 6. Trends in the costs among acute TSCI patients from 2013 to 2018

Figure supplement 1. Flow chart of case identification

In the end, a total of 14 754 patients from 37 hospitals in China were included in this study from 2013 to 2018. And the final number of cases included in the "surgery timing", the use of MPSS/MP, and the costs of acute TSCI during hospitalization were shown in the above figure. TSCI=traumatic spinal cord injury. EXCL=excluded. MPSS/MP=methylprednisolone sodium succinate/methylprednisolone.

695 **Table supplement 1. American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade**

AIS grade	Category	Description
A	Complete	No motor or sensory function is preserved in the sacral segments S4–S5
B	Incomplete	Sensory function preserved but not motor function is preserved below the neurological level and includes the sacral segments S4–S5
C	Incomplete	Motor function is preserved below the neurological level, and more than half of key muscles below the neurological level have a muscle grade less than 3
D	Incomplete	Motor function is preserved below the neurological level, and at least half of key muscles below the neurological level have a muscle grade of 3 or more
E	Normal	Motor and sensory function are normal, but still may have abnormal reflexes or other neurologic phenomena ^a .

696 ^a AIS grade E referred to the International standards for neurological classification of spinal cord injury [revised
697 2011] and an article from *J Spinal Cord Med* [Roberts TT, Leonard GR, Cepela DJ. Classifications In Brief:
698 American Spinal Injury Association (ASIA) Impairment Scale. *Clin Orthop Relat Res* 2017;**475**:1499-504.

Figure supplement 2. Trends in the percentage among TSCI patients of 23 hospitals from 2013 to 2018

(a) Trends in the percentage of TSCI in hospitalized patients of each hospital from 23 hospitals. (b) Trends in the percentage of TSCI in hospitalized patients through the orthopaedic departments of each hospital from 23 hospitals. TSCI=traumatic spinal cord injury. APC=annual percentage change. 95% CI=95% confidence interval.

02 **Table supplement 2. Trends in the percentage of different subgroups among TSCI patients from 2013 to 2018**

Category	2013	2014	2015	2016	2017	2018	APC (95% CI)
TSCI patients/Hospitalized patients							
Hospital type							
General hospital	0.000677437	0.000731737	0.000650481	0.000650376	0.000584477	0.000574924	-4.2 (-7.2, -1.0)
Orthopaedic hospital	0.004146887	0.004100949	0.003582044	0.004432452	0.004789523	0.004711542	3.8 (-2.2, 10.3)
Economic level							
Above the PCDI	0.000764280	0.000854571	0.000837578	0.000813096	0.000837774	0.000864237	1.5 (-1.1, 4.2)
Below the PCDI	0.001961198	0.001901074	0.001352715	0.002064160	0.001701302	0.001434080	-4.1 (-14.5, 7.6)
TSCI patients/Orthopaedic patients							
Hospital type							
General hospital	0.009496961	0.010165120	0.008524518	0.008521055	0.007753479	0.007722081	-5.1 (-8.4, -1.7)
Orthopaedic hospital	0.006207775	0.006087330	0.005567732	0.006757954	0.007892531	0.007828871	6.3 (-0.1, 13.1)
Economic level							
Above the PCDI	0.007594290	0.008133067	0.007529879	0.007149736	0.007625364	0.007885594	-0.2 (-3.3, 3.1)
Below the PCDI	0.010551825	0.010410185	0.006861413	0.010631962	0.008536560	0.007279922	-5.6 (-16.5, 6.8)

03 TSCI=traumatic spinal cord injury. APC=annual percentage change. 95% CI=95% confidence interval. PCDI=per capita disposable income.

Figure supplement 3. The trends of APC in the percentage among TSCI patients from 23 hospitals

(a) The trend of APC in the percentage among TSCI patients in hospitalized patients of different number of TSCI per year. (b) The trend of APC in the percentage among TSCI patients in hospitalized patients through the orthopaedic departments of different number of TSCI per year. The value of the horizontal axis represented the annual TSCI patients admitted. The APC corresponding to the points referred to the comprehensive calculation of APC from 2013 to 2018 of all eligible hospitals whose annual TSCI patients were more than the corresponding number of horizontal axis in 23 hospitals. Shaded regions represent 95% confidence interval. APC=annual percentage change. TSCI=traumatic spinal cord injury.

Table supplement 3. The use of MPSS/MP among TSCI patients during hospitalization

Category ^a	accumulated time≤2 d	3 d ≤accumulated time≤5 d	accumulated time≥6 d	No accumulated time ^b	Total
Use of MPSS/MP at over-instruction dose (≥500 mg)					
≤8 h	--	--	--	641	641
>8 h	--	--	--	1 443	1 443
Total	--	--	--	2 084	2 084
Use of MPSS/MP with normal instruction dose (<500 mg)					
Total					5 352
Continuous use of MPSS/MP with normal instruction dose					
≤1.6 d	495	439	320	--	1 254
1.6-9.0 d	897	923	629	--	2 449
≥9.0 d	505	553	251	--	1 309
Total	1 897	1 915	1 200	--	5 012
Intermittent use of MPSS/MP with normal instruction dose					
≤1.6 d	15	63	75	--	153
1.6-9.0 d	11	62	86	--	159
≥9.0 d	4	9	15	--	28
Total	30	134	176	--	340

^a The rows represented the start time of using MPSS/MP (h=hours, d=days), the columns represented the accumulated time of medication (d=days), and the figures represented the number of TSCI patients. ^b There is no accumulated time about use of MPSS/MP at over-instruction dose (≥500 mg). TSCI=traumatic spinal cord injury. MPSS/MP=methylprednisolone sodium succinate/methylprednisolone.

722 **Table supplement 4. The use of neurotrophic drugs, dehydrants and cathartics among TSCI patients**
723 **during hospitalization**

Category	Number of patients, n (%) ^a
Neurotrophic drugs	9 590 (65.0)
GM-1 ganglioside	4 979 (51.9)
Mouse nerve growth factor	2 785 (29.0)
Mecobalamin	2 580 (26.9)
Neurotrophin	1 927 (20.1)
Cattle encephalon glycoside and igitonin	550 (5.7)
Cobamamide	263 (2.7)
Others ^b	71 (0.7)
Dehydrants	8 898 (60.3)
Mannitol	7 558 (84.9)
Glycerin fructose	1 516 (17.0)
Sodium aescinate	366 (4.1)
Cathartics	1 508 (10.2)
Glycerin or glycerine enemas	1 434 (95.1)
Lactulose oral solution	128 (8.5)
Maren soft capsule	25 (1.7)

724 ^aThe overall use rate of neurotrophic drugs, dehydrants and cathartics was calculated by the proportion among
725 TSCI patients. The utilization rate of each drug was calculated by the proportion among patients who used
726 neurotrophic drugs, dehydrants or cathartics. ^b"others" included "Muscular amino acids and nucleosides" and/or
727 "Deproteinized calf blood extractive". TSCI=traumatic spinal cord injury.

28 **Table supplement 5. Trends in the length of hospital stay among acute TSCI patients from 2013 to 2018^a**

Category	Overall	2013	2014	2015	2016	2017	2018	APC (95% CI)
Gender, Mean (SD)								
Men	20.4 (27.1)	21.9 (20.7)	23.1 (40.1)	20.1 (23.7)	21.2 (25.8)	19.6 (28.6)	17.7 (17.9)	-4.2 (-7.5, -0.8)
Women	18.5 (23.2)	19.4 (16.8)	20.1 (19.5)	20.4 (26.4)	19.9 (25.4)	18.1 (30.3)	14.6 (15.0)	-4.9 (-10.7, 1.3)
Total	19.9 (26.2)	21.3 (19.8)	22.4 (36.5)	20.1 (24.3)	20.9 (25.7)	19.3 (29.0)	16.8 (17.2)	-4.5 (-8.1, -0.6)
Age groups, Mean (SD)								
15 years~	22.4 (31.6)	20.9 (14.9)	25.0 (26.2)	20.5 (24.0)	23.2 (22.8)	26.5 (64.6)	19.0 (16.2)	-0.5 (-9.5, 9.3)
25 years~	21.5 (25.3)	25.8 (29.4)	25.2 (29.8)	21.9 (30.2)	20.2 (19.1)	19.6 (22.2)	18.8 (21.6)	-6.7 (-8.8, -4.5)
35 years~	21.1 (35.1)	21.8 (22.2)	24.0 (62.8)	21.6 (28.7)	21.0 (27.6)	18.7 (21.8)	19.4 (23.7)	-3.8 (-7.4, -0.1)
45 years~	20.9 (25.9)	20.6 (14.7)	22.5 (23.9)	22.1 (27.4)	21.8 (29.0)	20.8 (32.4)	18.0 (18.5)	-2.6 (-7.1, 2.2)
55 years~	18.6 (19.9)	20.7 (19.2)	21.7 (27.6)	16.8 (14.5)	20.6 (22.5)	16.7 (20.0)	16.2 (12.5)	-5.0 (-11.1, 1.5)
≥ 65 years	16.9 (20.3)	19.3 (19.1)	16.9 (14.6)	18.1 (17.6)	19.5 (26.6)	18.2 (27.1)	12.5 (9.5)	-5.2 (-14.0, 4.5)

29 ^aLength of hospital stay was measured in days.

30 **Table supplement 6. Trends in the costs among acute TSCI patients from 2013 to 2018**

Category	2013	2014	2015	2016	2017	2018	APC (95% CI)
Total costs (CNY ¥ , thousand), Mean (SD)							
Gender							
Men	85.0 (79.8)	81.2 (85.1)	72.7 (62.2)	72.3 (64.3)	68.4 (75.4)	68.0 (67.3)	-4.6 (-6.5, -2.6)
Women	67.8 (58.4)	72.9 (108.0)	67.6 (69.3)	62.0 (54.1)	57.9 (47.1)	54.2 (46.3)	-5.3 (-8.4, -2.1)
Total	80.6 (75.3)	79.4 (90.8)	71.5 (63.8)	69.8 (62.2)	65.8 (69.7)	64.4 (62.8)	-4.8 (-6.2, -3.4)
Age groups							
15 years~	84.1 (58.9)	104.8 (201.5)	80.4 (70.1)	75.6 (51.9)	80.0 (96.2)	78.3 (59.8)	-3.5 (-10.2, 3.8)
25 years~	96.3 (100.6)	95.5 (93.9)	71.2 (66.4)	75.8 (61.4)	73.5 (56.8)	68.8 (46.1)	-6.6 (-11.8, -1.2)
35 years~	83.5 (90.1)	81.1 (98.9)	72.8 (53.8)	75.4 (70.7)	69.3 (51.4)	72.3 (97.6)	-3.3 (-5.8, -0.6)
45 years~	86.1 (68.6)	75.3 (61.9)	78.3 (68.8)	69.9 (69.1)	67.7 (61.4)	68.9 (61.4)	-4.3 (-7.2, -1.4)
55 years~	73.3 (65.7)	76.0 (74.8)	64.3 (56.2)	68.3 (53.7)	57.0 (46.4)	61.2 (52.8)	-4.8 (-8.9, -0.4)
≥ 65 years	61.6 (57.1)	63.6 (64.7)	63.7 (68.4)	59.0 (50.6)	62.4 (110.9)	50.3 (44.3)	-3.2 (-7.8, 1.6)
Daily costs (CNY ¥ , thousand), Mean (SD)							
Gender							
Men	4.5 (3.4)	4.3 (3.4)	4.4 (3.1)	4.2 (2.8)	4.5 (3.9)	4.5 (3.6)	0.3 (-1.8, 2.4)
Women	3.9 (3.6)	4.4 (3.9)	4.2 (3.5)	4.0 (3.3)	4.3 (3.3)	4.5 (3.5)	1.7 (-1.6, 5.2)
Total	4.4 (3.5)	4.3 (3.5)	4.3 (3.2)	4.2 (2.9)	4.4 (3.8)	4.5 (3.6)	0.5 (-1.2, 2.2)
Age groups							
15 years~	4.4 (3.0)	5.1 (5.6)	4.3 (2.6)	4.3 (3.2)	4.6 (3.0)	4.8 (3.0)	0.4 (-4.6, 5.6)
25 years~	4.6 (3.6)	4.6 (3.4)	4.4 (3.8)	4.3 (2.8)	4.7 (4.7)	4.5 (2.7)	-0.2 (-2.6, 2.2)
35 years~	4.6 (4.2)	4.5 (3.8)	4.4 (2.9)	4.5 (3.2)	4.7 (3.2)	4.3 (2.8)	-0.5 (-2.7, 1.7)
45 years~	4.6 (3.2)	4.3 (3.4)	4.6 (3.7)	4.1 (2.6)	4.5 (4.5)	4.5 (3.0)	-0.3 (-3.5, 3.1)
55 years~	4.2 (2.9)	4.2 (3.1)	4.1 (2.7)	4.1 (3.2)	4.2 (3.3)	4.5 (4.9)	1.0 (-1.1, 3.2)
≥ 65 years	3.8 (3.9)	3.9 (2.9)	4.0 (3.1)	3.8 (2.5)	4.2 (3.1)	4.5 (3.5)	2.9 (0.1, 5.9)

31 TSCI=traumatic spinal cord injury. APC=annual percentage change. 95% CI=95% confidence interval. CNY=Chinese Yuan. SD=standard deviation.

a **b**

a **b** **c**